Mass Humanization
  This platform is a radical new process to get access to human antibodies originally generated in immunized animals. It allows the immunization by different startegies (proteins, peptides, cDNA) and enables a batch humnisation process yielding fully human antibodies in a much faster and safer process than before.

Despite progress in capturing the immune system’s naïve antibody repertoire and optimization capabilities in synthetic libraries, immunized animals are still an attractive source of high affinity antibodies. However, humanization of such antibodies still respresent a high risk as one may loose affinity, specificity, expressibility and/or stability  We can meet the desire of our industry and generate antibodies in animals and turn such antibodies into human versions rapidly.

Rabbits are widely accepted as a source of high-quality antibody molecules. However, capacities of humanizations are usually limited and valuable candidates are too often lost or compromised in the process of humanization. AbCheck is able to provide partners access to the mass humanization of rabbit monoclonal antibodies and thereby generate human antibodies rapidly. The Mass Humanization technology, developed in partnership with Distributed Bio, is a radical new approach for multi-parameter engineering and optimization of monoclonal therapeutics. By analyzing the mutated repertoire of rabbits and humans, we were able to pre-compute and pre-encode the complete humanization landscape in a "mass humanization" technology, in which we humanize the in vivo immune response of a rabbit in a single experiment.

The technology enables us to both humanize and optimize monoclonal antibodies with respect to their affinity, stability and off-target specificity in a single process step. The ability to immunize these animals using antigens, peptide and cDNA as a starting point makes this approach ideally suited for the discovery of antibodies against a wide variety of targets.

  Imprint Disclaimer